JAZZ · earnings call history
Jazz Pharmaceuticals Q2 FY26 — Record Revenue and Raised Full-Year Guidance
Read the briefJazz Pharmaceuticals Q1 FY26 — Record Revenue and Zanidatamab Progress Drive Strong Start
Read the briefJazz Pharmaceuticals Q4 FY25 — Record Revenue and Strategic Focus on Rare Disease
Read the briefBrowse all US companies on the earnings-call register.